This website is intended for international healthcare professionals with an interest in the treatment of Nocturia. By clicking the link below you are declaring and confirming that you are a healthcare professional. Please answer a few short questions about this resource centre.

You are here

The effect of nocturia on sleep

Sleep Medicine Reviews, Volume 15, Issue 2, 2011, pages 91 - 97


Sleep plays a vital role in physical and mental functioning. It is increasingly recognized that disturbed sleep is a highly prevalent and chronic condition that merits greater awareness due to the wide-ranging and serious repercussions associated with it. Nocturia is one of the causes of sleep disturbance and has been shown to impair functioning, quality of life, health and productivity, with those experiencing two or more voids per night reporting significant ‘bother’. Nocturia warrants full consideration as a significant target for intervention, aiming to reduce the burden of disturbed sleep on individuals, families and society. Currently, however, a definitive evaluation of the most relevant sleep endpoints in nocturia therapy is lacking. One endpoint often used is the duration of the initial sleep period, which when evaluated in combination with the number of voiding episodes per night, might be an indication of the severity of sleep disruption in patients with nocturia.

Keywords: Nocturia, Sleep, Insomnia, Quality of life.

Abbreviations: ANP - atrial natriuretic peptide, CI - confidence interval, HR - hazard ratio, KHQ - King's Health Questionnaire, NP - nocturnal polyuria, N-QoL - nocturia-specific quality of life, OR - odds ratio, PSQI - Pittsburgh Sleep Quality Index, QALYs - quality-adjusted life years, QoL - quality of life.


a Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive #0733, San Diego, CA 92093-0733, USA

b Department of Neurology, Psychiatry/Behavioral Sciences, and Nursing, Program in Sleep, Aging and Chronobiology, Emory University School of Medicine, Wesley Woods Health Center, 1841 Clifton Road, Room 509, Atlanta, Ga 30329, USA

c Chief Scientific Officer Urology, Ferring Pharmaceuticals A/S, Medical Science Urology, International Pharmascience Center, Kay Fiskers Plads 11 DK- 2300 Copenhagen S, Denmark

d Department of Urology, University of Lund, Sweden

Corresponding author. Tel.: +1 858 822 7710; fax: +1 858 822 7712.

e Tel.: +1 404 728 4751; fax: +1 404 728 4756.

f Tel.: +45 2878 7547; fax: +45 28176548.